The role of medications for the management of patients with NAFLD.
The article is intended to provide an overview of the strengths and limits of controlled trials of pharmacologic treatment of nonalcoholic fatty liver disease. No drug has so far been approved, although validated on histologic outcomes. Several new drugs are under scrutiny, acting with different mechanisms along the chain of events from fatty liver to fibrosis, cirrhosis, and hepatocellular carcinoma. The article investigates which drug, if any, should be preferred for a tailored intervention in individual patients, according to age, comorbidities, and disease severity, and if treatment should be continued lifelong, to prevent disease progression and long-term occurrence of cirrhosis.
['Mazzella|Natalia|N|', 'Ricciardi|Laura M|LM|', 'Mazzotti|Arianna|A|', 'Marchesini|Giulio|G|']
D000975:Antioxidants D005234:Fatty Liver D006801:Humans D007004:Hypoglycemic Agents D000960:Hypolipidemic Agents D007333:Insulin Resistance D008687:Metformin D065626:Non-alcoholic Fatty Liver Disease D047492:Peroxisome Proliferator-Activated Receptors D016032:Randomized Controlled Trials as Topic D045162:Thiazolidinediones
Nonalcoholic fatty liver disease Anti-fibrotic agents Antioxidants Drug treatment Insuin-sensitizers PPAR agonists